

New Therapy Offers Hope for Patients with Advanced Cancer

NEWS PROVIDED BY

Rampart Health

September 16, 2025, 08:00 ET

Rampart Health's first-in-class salvage immunotherapy achieves systemic tumor regression in patients unresponsive to conventional treatment.

ORLANDO, Sept. 16, 2025 /PRNewswire/ – Rampart Health today announced the publication of results from its first-in-human, single-arm Phase 2 clinical trial (Abscopal 5001; NCT04713371) of *Multiplex IntraTumoral Immunotherapy (MITI™)* in the prestigious peer-reviewed journal *Cancers*. Results will also be presented at the International Cancer Conference (ICC 25) in London, UK, on September 18.

The MITI approach, designed as a salvage therapy for patients with metastatic cancer who have failed conventional treatment, integrates cryoablation with localized intratumoral delivery of a unique multiplexed immunotherapy cocktail (RPT-01-5001: low-dose pembrolizumab, ipilimumab, and cyclophosphamide) followed by GM-CSF. Unlike systemic immunotherapy, MITI is delivered directly into tumors, creating a personalized, *in situ* cancer vaccine that minimizes systemic toxicity while triggering a coordinated systemic immune attack.

Key Findings from the Published Study:

- **Disease Control:** Achieved in **77%** of patients (1 complete response, 4 partial responses, 5 stable disease).
- **Abscopal Effect:** Regression of untreated metastases in **31%** of patients, including biopsy-confirmed complete resolution of lung and liver metastases in bladder cancer patient and complete lung metastasis regression in sarcoma patient.
- **Durability:** Median overall survival was **20.9 months** and median progression-free survival was **5.4 months**.
- **Safety:** MITI was safe and well tolerated. 69% experienced only mild (Grade 1–2) side effects; 15% had transient Grade 3 complications. No Grade 4–5 events occurred.
- **Broad Utility:** Responses were observed across diverse cancers including prostate, sarcoma, bladder, colon, breast, kidney, cervical, tongue, and chordoma.

“These findings establish MITI as a fundamentally new paradigm in intratumoral immunotherapy,” said **David G. Bostwick, MD, MBA, CEO of Rampart Health**. “For patients who have exhausted conventional options, MITI offers a safe, outpatient salvage treatment with unprecedented abscopal responses and broad applicability across tumor types. By integrating multiple complementary immune activation pathways, we are creating a personalized, *in situ* cancer vaccine with the potential to transform the treatment of metastatic cancer.”

MITI distinguishes itself from other intratumoral approaches by simultaneously triggering four anti-cancer mechanisms with its multiplex design: (1) cryoablation releases the full complement of intact patient-specific tumor antigens, (2) intratumoral PD-1 and CTLA-4 blockade unmasks and unleashes T-cell activity, (3) low-dose cyclophosphamide reduces regulatory T-cell suppression, and (4) GM-CSF mobilizes effector immune cells. Together, these mechanisms consistently trigger systemic immune activation and abscopal tumor regressions rarely seen with systemic therapies alone.

About Rampart Health

Rampart Health is a clinical-stage company pioneering *Multiplex IntraTumoral Immunotherapy (MITI™)*, a novel, mechanistically rational, and personalized salvage therapy for patients with advanced metastatic cancer. MITI has demonstrated safety, feasibility, and broad tumor-type applicability in Phase II trials and is advancing toward larger confirmatory studies.

Publication available (free access) online:

Cancers 2025, 17(18), 2990

<https://www.mdpi.com/2072-6694/17/18/2990>

Contact:

David G. Bostwick, MD, MBA

CEO, Rampart Health

dbostwick@ramparthealth.com

SOURCE: Rampart Health